Decision and Details
U.S. Patent Allowance for Combination of a Humanized DLK-1 Antibody and an FGFR4 Inhibitor
Because we believe this will strengthen the intellectual property foundation supporting our development and out-licensing activities.
This matter will have no impact on results for the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Matter Covered | U.S. Patent Allowance for Combination of a Humanized DLK-1 Antibody and an FGFR4 Inhibitor |
| Decision Date | 16 November 2026 (date the notice of allowance was received) |
| Quantity / scale | U.S. patent application No.18/030,203 |
| Impact on Business Performance | This matter will have no impact on results for the fiscal year ending December 2026. |
| Reason | Because we believe this will strengthen the intellectual property foundation supporting our development and out-licensing activities. |
| Future plans | Patent applications are also pending in Europe, China and other jurisdictions. For CBA-1205, we aim to out-license the product to a pharmaceutical company using safety and preliminary efficacy data obtained from the domestic Phase 1 clinical trial. |
| Title of invention | Pharmaceutical for cancer treatment |
| Patent holder | Chiome Bioscience Inc. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the intellectual property foundation supporting our development and out-licensing activities.